Macquarie Group’s aTyr Pharma ATYR Stock Holding History

Macquarie Group’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,243	Closed	-$9K	–	2070
2018 Q4	$9K	Buy	+1,243	New	+$10.4K	﹤0.01%	1947

Other funds holding ATYR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GHCM

Glen Harbor Capital Management San Diego, California $4.82B AUM 4.69% 1-Year Est. Return

MCIM

Meadow Creek Investment Management Atlanta, Georgia $5.09B AUM 5.82% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group's ATYR Position: Q1 2019 in Review

Macquarie Group sold out of aTyr Pharma (ATYR) in Q1 2019, closing a stake of 1,243 shares — an estimated $9K sold.

Macquarie Group first reported a position in ATYR in Q4 2018 and held it in 1 quarter. The position peaked at $9K in Q4 2018. 27 funds tracked by Wall St. Rank hold ATYR as of Q1 2019.

Macquarie Group reported no remaining aTyr Pharma position as of Q1 2019 after selling out during the quarter.
Macquarie Group sold 1,243 aTyr Pharma shares in Q1 2019, an estimated $9K.
Macquarie Group first reported a position in aTyr Pharma in Q4 2018 and held it in 1 quarter.
Macquarie Group's aTyr Pharma position peaked at $9K in Q4 2018.
27 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.